Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 6, 2011, Pages 978-987

  Osorio, Jorge E ^a,b   Brewoo, Joseph N ^a,b   Silengo, Shawn J ^c   Arguello, John ^c,d   Moldovan, Ioana R ^e   Tary Lehmann, Magdalena ^e   Powell, Tim D ^c   Livengood, Jill A ^c   Kinney, Richard M ^c,d   Huang, Claire Y H ^d   Stinchcomb, Dan T ^c  

^a Inviragen   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Inviragen Inc   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e Cellular Technology Limited   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; IMMUNIZATION; IMMUNOGENICITY; MACACA FASCICULARIS; NONHUMAN; TREATMENT RESPONSE; VIREMIA; VIRUS ATTENUATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; IMMUNITY, CELLULAR; MACACA FASCICULARIS; NEUTRALIZATION TESTS; RNA, VIRAL; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS; VIREMIA;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS GROUP; MACACA; MACACA FASCICULARIS; PRIMATES;

EID: 79958710286     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0592     Document Type: Article

References (41)

1. Guzman MG, Kouri G, 2002. Dengue: an update. Lancet Infect Dis 2: 33-42. (Pubitemid 36109304)
2. Wilder-Smith A, Gubler DJ, 2008. Geographic expansion of dengue: the impact of international travel. Med Clin North Am 92: 1377-1390.
3. Gubler DJ, 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 277: 3-16; discussion 16-22, 71-73, 251-253.
4. Kyle JL, Harris E, 2008. Global spread and persistence of dengue. Annu Rev Microbiol 62: 71-92.
5. Henchal EA, Putnak JR, 1990. The dengue viruses. Clin Microbiol Rev 3: 376-396.
6. Halstead SB, 1970. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42: 350-362.
7. Halstead SB, 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239: 476-481. (Pubitemid 18084309)
8. Halstead SB, 2002. Vaccines aplenty. Curr Opin Infect Dis 15: 461-463.
9. Gubler DJ, 1998. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480-496. (Pubitemid 28379096)
10. Halstead SB, Deen J, 2002. The future of dengue vaccines. Lancet 360: 1243-1245. (Pubitemid 35232727)
11. Kinney RM, Huang CY, 2001. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44: 176-197. (Pubitemid 32757396)
12. Yoksan S, Bhamarapravati N, Halstead S, 1986. Dengue virus vaccine development: study on biological markers of cloned dengue 1-4 viruses serially passaged in primary kidney cells. St. George TD, Kay BH, Blok J, eds. Arbovirus Research in Australia. Proceedings of the Fourth Symposium. Brisbane, Australia: Commonwealth Scientific and Industrial Research Organisation/Queensland Institute of Medical Research, 35-38.
13. Vaughn DW, Hoke CH Jr, Yoksan S, LaChance R, Innis BL, Rice RM, Bhamarapravati N, 1996. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14: 329-336. (Pubitemid 26126437)
14. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N, 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272. (Pubitemid 34756095)
15. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr, 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19: 3179-3188. (Pubitemid 32324047)
16. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A, 1987. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ 65: 189-195. (Pubitemid 17089851)
17. Dharakul T, Kurane I, Bhamarapravati N, Yoksan S, Vaughn DW, Hoke CH, Ennis FA, 1994. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J Infect Dis 170: 27-33. (Pubitemid 24186421)
18. Rothman AL, Kanesa-thasan N, West K, Janus J, Saluzzo JF, Ennis FA, 2001. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 19: 4694-4699. (Pubitemid 32800752)
19. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, Gubler DJ, 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230: 300-308. (Pubitemid 27211861)
20. Butrapet S, Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM, 2000. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol 74: 3011-3019. (Pubitemid 30143723)
21. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM, 2003. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77: 11436-11447. (Pubitemid 37271642)
22. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM, 2000. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74: 3020-3028. (Pubitemid 30143724)
23. Men R, Wyatt LS, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, Lai CJ, 2000. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18: 3113-3122. (Pubitemid 30345693)
24. Halstead SB, Palumbo NE, 1973. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. Am J Trop Med Hyg 22: 375-381.
25. Halstead SB, Shotwell H, Casals J, 1973. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 128: 15-22.
26. Halstead SB, Shotwell H, Casals J, 1973. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128: 7-14.
27. Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus AD, 2007. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine 25: 5409-5416. (Pubitemid 46977528)
28. Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus AD, 2007. Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses. Microbes Infect 9: 940-946. (Pubitemid 46921016)
29. Blaney JE Jr, Johnson DH, Firestone CY, Hanson CT, Murphy BR, Whitehead SS, 2001. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in Vero cells or human liver cells and attenuated in mice. J Virol 75: 9731-9740. (Pubitemid 32900108)
30. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J, 2009. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80: 302-311.
31. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP, 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298: 146-159. (Pubitemid 34734888)
32. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T, 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78: 4761-4775. (Pubitemid 38501097)
33. Butrapet S, Kinney RM, Huang CY, 2006. Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods 131: 1-9. (Pubitemid 41772553)
34. Houng HS, Chung-Ming Chen R, Vaughn DW, Kanesa-thasan N, 2001. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3′ noncoding sequences. J Virol Methods 95: 19-32. (Pubitemid 32493834)
35. Huang CY, Butrapet S, Moss KJ, Childers T, Erb SM, Calvert AE, Silengo SJ, Kinney RM, Blair CD, Roehrig JT, 2010. The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology 396: 305-315.
36. Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M, 2003. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 278: 79-93. (Pubitemid 37281194)
37. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, Trezza RP, Heinzel FP, Forsthuber T, Lehmann PV, 1999. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162: 3942-3949. (Pubitemid 29314773)
38. Halstead SB, 2008. Dengue virus-mosquito interactions. Annu Rev Entomol 53: 273-291. (Pubitemid 351341942)
39. Brault A, Kinney R, Maharaj P, Green E, Reisen W, Huang CY, 2011. Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5′ untranslated region and amino acid substitutions in nonstructural proteins 1 and 3. Vector Borne Zoonotic Dis [E pub ahead of print].
40. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T, 2010. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28: 2705-2715.
41. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS, 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79: 5516-5528. (Pubitemid 40548220)